AU748442B2 - Vertebrate telomerase genes and proteins and uses thereof - Google Patents

Vertebrate telomerase genes and proteins and uses thereof Download PDF

Info

Publication number
AU748442B2
AU748442B2 AU82854/98A AU8285498A AU748442B2 AU 748442 B2 AU748442 B2 AU 748442B2 AU 82854/98 A AU82854/98 A AU 82854/98A AU 8285498 A AU8285498 A AU 8285498A AU 748442 B2 AU748442 B2 AU 748442B2
Authority
AU
Australia
Prior art keywords
telomerase
nucleic acid
acid molecule
sequence
region
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU82854/98A
Other languages
English (en)
Other versions
AU8285498A (en
Inventor
David Bowtell
Andrzej Kilian
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CAMBIA
Original Assignee
Peter MacCallum Cancer Institute
Monticello Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Peter MacCallum Cancer Institute, Monticello Group Ltd filed Critical Peter MacCallum Cancer Institute
Publication of AU8285498A publication Critical patent/AU8285498A/en
Assigned to Monticello Group, Ltd., The, PETER MACCALLUM CANCER INSTITUTE, THE reassignment Monticello Group, Ltd., The Alteration of Name(s) of Applicant(s) under S113 Assignors: CAMBIA BIOSYSTEMS LLC, PETER MACCALLUM CANCER INSTITUTE, THE
Application granted granted Critical
Publication of AU748442B2 publication Critical patent/AU748442B2/en
Assigned to CAMBIA reassignment CAMBIA Alteration of Name(s) in Register under S187 Assignors: Monticello Group, Ltd., The, PETER MACCALLUM CANCER INSTITUTE, THE
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52—Genes encoding for enzymes or proenzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1241—Nucleotidyltransferases (2.7.7)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Plant Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
AU82854/98A 1997-07-01 1998-07-01 Vertebrate telomerase genes and proteins and uses thereof Ceased AU748442B2 (en)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US5141097P 1997-07-01 1997-07-01
US60/051410 1997-07-01
US5301897P 1997-07-21 1997-07-21
US5332997P 1997-07-21 1997-07-21
US60/053018 1997-07-21
US60/053329 1997-07-21
US5464297P 1997-08-04 1997-08-04
US60/054642 1997-08-04
US5828797P 1997-09-09 1997-09-09
US60/058287 1997-09-09
PCT/US1998/013835 WO1999001560A1 (en) 1997-07-01 1998-07-01 Vertebrate telomerase genes and proteins and uses thereof

Publications (2)

Publication Number Publication Date
AU8285498A AU8285498A (en) 1999-01-25
AU748442B2 true AU748442B2 (en) 2002-06-06

Family

ID=27535157

Family Applications (1)

Application Number Title Priority Date Filing Date
AU82854/98A Ceased AU748442B2 (en) 1997-07-01 1998-07-01 Vertebrate telomerase genes and proteins and uses thereof

Country Status (9)

Country Link
US (3) US6846662B1 (https=)
EP (1) EP0917579A1 (https=)
JP (1) JP2002514928A (https=)
KR (1) KR100581990B1 (https=)
CN (1) CN1270634A (https=)
AU (1) AU748442B2 (https=)
CA (1) CA2294782A1 (https=)
IL (1) IL133830A0 (https=)
WO (1) WO1999001560A1 (https=)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6475789B1 (en) 1996-10-01 2002-11-05 University Technology Corporation Human telomerase catalytic subunit: diagnostic and therapeutic methods
US6808880B2 (en) 1996-10-01 2004-10-26 Geron Corporation Method for detecting polynucleotides encoding telomerase
US7585622B1 (en) 1996-10-01 2009-09-08 Geron Corporation Increasing the proliferative capacity of cells using telomerase reverse transcriptase
US6261836B1 (en) 1996-10-01 2001-07-17 Geron Corporation Telomerase
US6093809A (en) 1996-10-01 2000-07-25 University Technology Corporation Telomerase
US6610839B1 (en) * 1997-08-14 2003-08-26 Geron Corporation Promoter for telomerase reverse transcriptase
US6777203B1 (en) 1997-11-19 2004-08-17 Geron Corporation Telomerase promoter driving expression of therapeutic gene sequences
IL129222A0 (en) 1996-10-01 2000-02-17 Geron Corp Telomerase reverse transcriptase
US7622549B2 (en) 1997-04-18 2009-11-24 Geron Corporation Human telomerase reverse transcriptase polypeptides
KR100581990B1 (ko) * 1997-07-01 2006-05-23 캄비아 바이오시스템즈 엘엘씨 척추 동물 텔로머라제 유전자 및 단백질과 이의 용도
US7378244B2 (en) 1997-10-01 2008-05-27 Geron Corporation Telomerase promoters sequences for screening telomerase modulators
WO1999027113A1 (en) * 1997-11-26 1999-06-03 Geron Corporation Mouse telomerase reverse transcriptase
DE69931600T2 (de) 1998-01-08 2007-05-03 Chugai Seiyaku K.K. Neues gen mit einem revers-transkriptase-motiv
US7402307B2 (en) 1998-03-31 2008-07-22 Geron Corporation Method for identifying and killing cancer cells
US6337200B1 (en) 1998-03-31 2002-01-08 Geron Corporation Human telomerase catalytic subunit variants
EP1068296B1 (en) 1998-03-31 2011-08-10 Geron Corporation Compositions for eliciting an immune response to a telomerase antigen
DE19916929A1 (de) 1999-04-15 2000-10-19 Bayer Ag Ein automatisierbarer Schnelltest zum Nachweis von Krebserkrankungen auf der Basis von Telomerase(hTC) mRNA mit spezifischen Primern und Sonden
US6210950B1 (en) * 1999-05-25 2001-04-03 University Of Medicine And Dentistry Of New Jersey Methods for diagnosing, preventing, and treating developmental disorders due to a combination of genetic and environmental factors
US6912492B1 (en) 1999-05-25 2005-06-28 University Of Medicine & Dentistry Of New Jersey Methods for diagnosing, preventing, and treating developmental disorders due to a combination of genetic and environmental factors
US6664046B1 (en) * 1999-12-16 2003-12-16 Roche Molecular Systems, Inc. Quantitation of hTERT mRNA expression
KR20010096991A (ko) * 2000-04-19 2001-11-08 임정빈 텔로머레이즈의 프로모터에 특정하게 결합하는더블유티이1 절편, 그 유전자, 발현벡터 및 그것을 이용한세포성장 억제 방법
AUPQ923400A0 (en) * 2000-08-07 2000-08-31 Children's Medical Research Institute Assays for alternative lengthening of telomeres
US7078491B1 (en) 2000-09-21 2006-07-18 Amgen Inc. Selective binding agents of telomerase
GB0031430D0 (en) * 2000-12-22 2001-02-07 Norsk Hydro As Polypeptides
GB0112342D0 (en) * 2001-05-21 2001-07-11 Norsk Hydro As Polypeptides
US20050244969A1 (en) * 2001-10-18 2005-11-03 Jan-Heiner Kupper Transient immortalization
US20060127909A1 (en) * 2002-12-06 2006-06-15 Bernd Schwenzer Polynucleotides targeted against hter and use thereof
EP1748067A1 (en) * 2005-07-29 2007-01-31 Institut Pasteur Polynucleotides encoding MHC class I-restricted hTERT epitopes, analogues thereof or polyepitopes
CA3057039C (en) * 2006-07-28 2023-02-28 The Trustees Of The University Of Pennsylvania Hiv consensus envelope sequences and methods for using same
EP1994942A1 (en) * 2007-05-25 2008-11-26 INSERM (Institut National de la Santé et de la Recherche Médicale) Pharmaceutical compositions comprising telomerase, and uses thereof
PL2536830T3 (pl) 2010-02-16 2020-02-28 Ultimovacs As Polipeptydy
RU2468030C2 (ru) 2010-04-09 2012-11-27 Государственное учебно-научное учреждение Химический факультет Московского государственного университета им. М.В. Ломоносова Ингибиторы теломеразы и способ их получения
WO2013169060A1 (ko) 2012-05-11 2013-11-14 주식회사 카엘젬백스 패혈증 예방 또는 치료용 조성물
ES2691070T3 (es) 2012-05-11 2018-11-23 Kael-Gemvax Co.,Ltd Péptidos antiinflamatorios y composición que comprende los mismos
ES2981865T3 (es) 2012-07-11 2024-10-10 Gemvax & Kael Co Ltd Conjugado que comprende un péptido de penetración celular y composiciones que comprenden el mismo
US20150125438A1 (en) * 2012-07-20 2015-05-07 Sang Jae Kim Anti-Inflammatory Peptides and Composition Comprising the Same
TWI616531B (zh) * 2012-09-19 2018-03-01 傑姆維克斯＆凱爾有限公司 穿膜胜肽以及包含該胜肽之共軛物及組成物（二）
US9445603B2 (en) 2013-03-15 2016-09-20 Monsanto Technology Llc Compositions and methods for the production and delivery of double stranded RNA
KR102258864B1 (ko) 2013-04-19 2021-06-01 주식회사 젬백스앤카엘 허혈성 손상 치료 및 예방용 조성물
RU2677277C2 (ru) 2013-06-07 2019-01-16 Джемвакс Энд Каэл Ко., Лтд. Биологические маркеры, которые могут быть использованы в иммунотерапии рака
TWI539960B (zh) 2013-06-21 2016-07-01 凱爾傑姆維克斯有限公司 激素分泌調節劑、包括其的組成物以及其用途
US9757473B2 (en) * 2013-07-12 2017-09-12 Gemvax & Kael Co., Ltd. Cell-penetrating peptide and conjugate comprising same
CA2926183C (en) 2013-10-23 2018-07-03 Gemvax & Kael Co., Ltd. Composition for treating and preventing benign prostatic hyperplasia
EP3072519B1 (en) 2013-11-22 2020-08-19 Gemvax & Kael Co., Ltd. Peptide having angiogenesis inhibitory activity and composition containing same
ES2809251T3 (es) 2013-12-17 2021-03-03 Gemvax & Kael Co Ltd Composición para tratar cáncer de próstata
JP6420459B2 (ja) 2014-04-11 2018-11-07 ジェムバックス アンド カエル カンパニー，リミティド 線維症抑制活性を有するペプチド及びこれを含む組成物
US10662223B2 (en) 2014-04-30 2020-05-26 Gemvax & Kael Co., Ltd. Composition for organ, tissue, or cell transplantation, kit, and transplantation method
KR102413243B1 (ko) 2014-12-23 2022-06-27 주식회사 젬백스앤카엘 안질환 치료 펩티드 및 이를 포함하는 안질환 치료용 조성물
KR102636129B1 (ko) 2015-02-27 2024-02-14 주식회사 젬백스앤카엘 청력 손상 방어용 펩타이드 및 이를 포함하는 조성물
EP3318265B1 (en) 2015-07-02 2021-08-18 Gemvax & Kael Co., Ltd. Peptide having anti-viral effect and composition containing same
CN108289909A (zh) 2015-10-19 2018-07-17 巴尔的摩马里兰大学 用于产生工程改造的人原代血液树突细胞系的方法
EP4272829A3 (en) 2016-04-07 2024-01-17 Gemvax & Kael Co., Ltd. Peptide having effects of increasing telomerase activity and extending telomere, and composition containing same
CN110117644A (zh) * 2019-04-18 2019-08-13 王金固 一种用于生物样本中rna的基因检测方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5489508A (en) 1992-05-13 1996-02-06 University Of Texas System Board Of Regents Therapy and diagnosis of conditions related to telomere length and/or telomerase activity
US5639613A (en) 1992-05-13 1997-06-17 Board Of Regents, University Of Texas System Methods for cancer diagnosis and prognosis
US5645986A (en) 1992-05-13 1997-07-08 Board Of Reagents, The University Of Texas System Therapy and diagnosis of conditions related to telomere length and/or telomerase activity
WO1995013382A1 (en) * 1993-11-12 1995-05-18 Geron Corporation Therapy and diagnosis of conditions related to telomere length and/or telomerase activity
RO117328B1 (ro) * 1994-07-07 2002-01-30 Geron Corp Componenta rna a telomerazei de mamifere, plasmida recombinanta, de exprimare a acesteia, si metoda pentru detectarea prezentei unei stari neoplazice
US5972605A (en) 1994-07-07 1999-10-26 Geron Corporation Assays for regulators of mammalian telomerase expression
EP0799315A2 (en) * 1994-12-19 1997-10-08 Cold Spring Harbor Laboratory Telomerase protein component
US5770422A (en) 1996-07-08 1998-06-23 The Regents Of The University Of California Human telomerase
IL129222A0 (en) 1996-10-01 2000-02-17 Geron Corp Telomerase reverse transcriptase
US6261836B1 (en) 1996-10-01 2001-07-17 Geron Corporation Telomerase
US6093809A (en) * 1996-10-01 2000-07-25 University Technology Corporation Telomerase
US7390891B1 (en) * 1996-11-15 2008-06-24 Amgen Inc. Polynucleotides encoding a telomerase component TP2
US5919656A (en) 1996-11-15 1999-07-06 Amgen Canada Inc. Genes encoding telomerase protein 1
WO1998037181A2 (en) * 1997-02-20 1998-08-27 Whitehead Institute For Biomedical Research Telomerase catalytic subunit gene and encoded protein
KR100581990B1 (ko) * 1997-07-01 2006-05-23 캄비아 바이오시스템즈 엘엘씨 척추 동물 텔로머라제 유전자 및 단백질과 이의 용도

Also Published As

Publication number Publication date
US20050176022A1 (en) 2005-08-11
US6846662B1 (en) 2005-01-25
CN1270634A (zh) 2000-10-18
KR20010020601A (ko) 2001-03-15
EP0917579A1 (en) 1999-05-26
US6916642B1 (en) 2005-07-12
KR100581990B1 (ko) 2006-05-23
AU8285498A (en) 1999-01-25
JP2002514928A (ja) 2002-05-21
CA2294782A1 (en) 1999-01-14
WO1999001560A1 (en) 1999-01-14
IL133830A0 (en) 2001-04-30

Similar Documents

Publication Publication Date Title
AU748442B2 (en) Vertebrate telomerase genes and proteins and uses thereof
US6043083A (en) Inhibitors of the JNK signal transduction pathway and methods of use
Kermouni et al. The IL-9 receptor gene (IL9R): genomic structure, chromosomal localization in the pseudoautosomal region of the long arm of the sex chromosomes, and identification of IL9R pseudogenes at 9qter, 10pter, 16pter, and 18pter
Laverty et al. Murine CASK is disrupted in a sex-linked cleft palate mouse mutant
US6300110B1 (en) Peptides related to TPC2 and TPC3, two proteins that are coexpressed with telomerase activity
AU745420B2 (en) Human catalytic telomerase sub-unit and its diagnostic and therapeutic use
US6277979B1 (en) KIAA0551 polynucleotides and polypeptides use
US6586577B2 (en) Telomere repeat binding factors and diagnostic and therapeutic use thereof
Shirsat et al. Structure of the murine lactotransferrin gene is similar to the structure of other transferrin-encoding genes and shares a putative regulatory region with the murine myeloperoxidase gene
US20040142357A1 (en) Novel telomerase inhibitors and uses therefor
Kelter et al. The transcription factor-like nuclear regulator (TFNR) contains a novel 55-amino-acid motif repeated nine times and maps closely to SMN1
WO2000061813A1 (en) A second mammalian tankyrase
EP1571215A2 (en) Vertebrate telomerase genes and proteins and uses thereof
US6815532B2 (en) ATR-2 cell cycle checkpoint
CA2324445A1 (en) Blk genes, gene products and uses thereof in apoptosis
MXPA00000196A (en) Vertebrate telomerase genes and proteins and uses thereof
EP1364025B1 (en) A novel gene bno1 mapping to chromosome 16q24.3
HK1032074A (en) Vertebrate telomerase genes and proteins and uses thereof
WO2002026246A2 (en) Pharmaceutical compositions comprising polynucleotides encoding a raf protein
CA2261297A1 (en) A novel maturation-inhibited protein kinase
JP2001245669A (ja) 新規シチジンデアミナーゼ
JP2003088376A (ja) ヒト・キナーゼｍａｓｋとその遺伝子

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: THE NAME OF THE APPLICANT IN REGARD TO PATENT APPLICATION NUMBER 82854/98 SHOULD INCLUDE: PETER MACCULLUM CANCER INSTITUTE

PC1 Assignment before grant (sect. 113)

Owner name: THE MONTICELLO GROUP, LTD., PETER MACCULLUM CANCER

Free format text: THE FORMER OWNER WAS: CAMBIA BIOSYSTEMS LLC, PETER MACCULLUM CANCER INSTITUTE

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND 2ND APPLICANT'S NAME TO READ: PETER MACCALLUM CANCER INSTITUTE

FGA Letters patent sealed or granted (standard patent)
NB Applications allowed - extensions of time section 223(2)

Free format text: THE TIME IN WHICH TO PROVIDE SEARCH RESULTS UNDER S45(3) HAS BEEN EXTENDED TO 20040301